Skip to main content
Log in

Neuroleptic Malignant Syndrome — follow-up study

  • Published:
Irish Journal of Medical Science Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kellam, A. M. P. The Neuroleptic Malignant Syndrome, so-called. Brit. J. Psych. 1987: 150, 752–759.

    Article  CAS  Google Scholar 

  2. Keck, K. E., Pope, H. G., McElroy, S. L. Frequency and presentation of Neuroleptic Malignant Syndrome: A prospective study. Am. J. Psych. 1987: 144, 1344–1346.

    Google Scholar 

  3. Levenson, J. L., Fisher, J. G. Long-term outcome after Neuroleptic Malignant Syndrome. J. Clin. Psychiatry. 1988: 49, 154–156.

    PubMed  CAS  Google Scholar 

  4. Gelenberg, A. J., Bellinghausen, Wojcik, J. D., Falk, W. E., Farhadi, A. M. Patients with Neuroleptic Malignant Syndrome histories: what happens to them when they are re-hospitalised? J. Clin. Psychiatry, 1989: 50, 178–180.

    PubMed  CAS  Google Scholar 

  5. Rosebush, P., Stewart, T. Twenty neuroleptic rechallenges after Neuroleptic Malignant Syndrome in 15 patients. J. Clin. Psychiatry. 1989: 50 295–298.

    PubMed  CAS  Google Scholar 

  6. Freyne, ?., McCarthy, A. Neuroleptic Malignant Syndrome: nine cases. Ir. J. Med. Sci. 1988: 157, 321–323.

    Article  PubMed  CAS  Google Scholar 

  7. McCarthy, ?., Bourke, S., Fahy, J., Binchy, I., Fitzgerald, M. X. Fatal recurrence of Neuroleptic Malignant Syndrome. Brit. J. Psych. 1988: 152, 558–559.

    Article  CAS  Google Scholar 

  8. Shulack, N. R. Sudden ‘exhaustive” death in excited patients. Psychi-atr. Q. 1944: 18, 3–12.

    Article  Google Scholar 

  9. Fiebel, J. H., Schiffer, R. B. Sympathoadrenomedullary hyperactivity in the Neuroleptic Malignant Syndrome. Am. J. Psych. 1981: 138, 1115–1116.

    Google Scholar 

  10. Schidruk, M., Schachter, D. A role for catecholamines in the pathogenesis of Neuroleptic Malignant Syndrome. Can. J. Psych. 1986: 31, 66–69.

    Google Scholar 

  11. Rosebush, P., Stewart, T. A prospective analysis of 24 episodes of Neuroleptic Malignant Syndrome. Am. J. Psych. 1989: 146, 717–725.

    CAS  Google Scholar 

  12. Keck, P. E., Pope, H. E., Cohen, B. M., McElroy, S. L., Nierenberg, A. A. Risk factors for Neuroleptic Malignant Syndrome. Arch. Gen. Psychiatry. 1989: 46, 914–918.

    PubMed  Google Scholar 

  13. Bayés de Luna, A., Coumel, P., Leclercq, J. F. Ambulatory sudden cardiac death: mechanisms of production of fatal arrhythmia on the basis of data from 157 cases. Am. Heart J. 1989: 117, 151–159.

    Article  Google Scholar 

  14. Bellavere, F., Ferri, M., Guarini, L., Bay, G., Piccoli, A., Cardone, Fedale, D. Prolonged QT period in diabetic autonomic neuropathy: a possible role in sudden cardiac death. Br. Heart J. 1988: 59, 379–83.

    Article  PubMed  CAS  Google Scholar 

  15. May, D. C., Morris, S. W., Stewart, R. M., Fenton, B. J., Gaffney, F. A. Neuroleptic Malignant Syndrome: Response to Dantrolene Sodium. Ann. Int. Med. 1983: 98, 183–184.

    PubMed  CAS  Google Scholar 

  16. Goldwasser, H. D., Hooper, J. F., Spears, N. M. Concomitant treatment of Neuroleptic Malignant Syndrome and psychosis. Brit. J. Psych. 1989: 154, 102–104.

    Article  CAS  Google Scholar 

  17. Padgett, R., Lipman, E. Use of Neuroleptics after an episode of Neuroleptic Malignant Syndrome. Can. J. Psych. 1989: 34, 323–325.

    CAS  Google Scholar 

  18. Wells, A.J., Sommi, R.W., Crimson, M.L. Neuroleptic challenge after Neuroleptic Malignant Syndrome: Case report and literature review. Drug Intell. Clin. Pharm. 1988: 22, 475–480.

    PubMed  CAS  Google Scholar 

  19. Shalev, A., Munitz, H. The Neuroleptic Malignant Syndrome: agent and host interaction. Acta Psychiatr. Scand. 1986: 73, 337–347.

    Article  PubMed  CAS  Google Scholar 

  20. Hermesh, H., Huberman, M., Rodvan, H., Kott, E. Single case study: recurrent Neuroleptic Malignant Syndrome due to tiapride and Haloperidol: the possible role of D-2 dopamine receptors. J. Nerv. Ment. Dis. 1984: 172, 692–695.

    Article  PubMed  CAS  Google Scholar 

  21. Olmsted, J. R. Neuroleptic Malignant Syndrome. Guidelines for treatment and reinstitution of treatment. South Med. J. 1988: 81, 888–891.

    Article  PubMed  CAS  Google Scholar 

  22. Susman, V. L., Addonizio, G. Re-introduction of Neuroleptic Malignant Syndrome by lithium. J. Clin. Psychopharmacol. 1987: 5, 339–341.

    Google Scholar 

  23. Caroff, S., Rosenberg, H., Gerber, J. Neuroleptic Malignant Syndrome and malignant hyperthermia. Lancet 1983: i, 244.

    Article  Google Scholar 

  24. Addonizio, G., Susman, V. L. as a treatment alternative for patients with symptoms of Neuroleptic Malignant Syndrome. J. Clin, Psychiatry 1987: 48, 102–105.

    CAS  Google Scholar 

  25. Hermesh, H., Aizenberg, D., Lapidot, M., Munitz, M. The relationship between malignant hyperthermia and Neuroleptic Malignant Syndrome. Anaesthesiol. 1989: 70, 172–173.

    Article  Google Scholar 

  26. Buckley, P., Carmody, E., Hutchinson, M. Wilson’s disease and the Neuroleptic Malignant Syndrome. Ir. J. Psycholog. Med. (in press, 1990).

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buckley, P., Freyne, A., McCarthy, A. et al. Neuroleptic Malignant Syndrome — follow-up study. I.J.M.S. 160, 45–47 (1991). https://doi.org/10.1007/BF02947643

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02947643

Keywords

Navigation